PartⅢ Script of the Audiovisual Material
The Future of Healthcare：Where Will We be in 2023
It is difficult to predict what we might be doing in biopharmaceutical research and development in the future,but let's think about some of the types of things we might doing by 2023：intelligent medicines,personalised healthcare,regenerative medicine,gene and Oligo-based therapy,drug delivery systems,and finally the global marketplace.
Int6llig6nt M 6dicin6s
What does intelligent medicines mean？Well,if you think about it,72%of the global population currently have mobile phones.Then consider how many people around social media platforms like Facebook,and how we use websites like Amazon and Google,there is huge opportunity in the way we socialize and use technology today that the healthcare industry could utilize.We already know that,with things like pacemakers and diabetes care,there are remote ways of monitoring cardiac function and blood sugar levels,which is having a dramatic impact in terms of reducing hospitalization rates,but imagine what would happen in a world where your pill had a sensor on it and could detect your blood cholesterol or your blood sugar or your pulse,and could send a message to your smart phone or directly to your physician about whether you need to increase or decrease your dose.This is not beyond the realms of the reality.Pills and medicines are starting to have these types of sensors and chips built into them.2023 may be a little soon.But over the next two decades,it is likely that we will start to see some of these technologies manifesting themselves in the marketplace.
P6rsonalis6d H6althcar6
Great strides have been made in the oncology space with respect to personalized healthcare,but more can be done across all disease areas.There are companion diagnostics now being approved by regulators.And we are starting to see panels of diagnostics being used.This will mean at the start of diagnosis a panel of tests can be performed,so that therapy can be tailored to the type of mutation and make for the better prognosis.This approach will become more commonplace as it becomes more familiar with physicians.We will start to see it being adopted in the emerging markets as well.In the long term,we could see a time when physicians don't just run a genome analysis but also a metabolism analysis and a protein analysis to get a really thorough understanding of what is driving the disease.This could be done using a number of different techniques via a small chip that will give physicians much better clarity at how to tailor available therapies.Although a potential challenge will be the management of the large quantity of data generated from such devices.
R6g6n6rativ6 M6dicin6
Regenerative medicine is to repair or,more accurately,help the body repair and replace lost or damaged tissue rather than to just destroy or remove the damaged or diseased tissue or to replace it with nonbiological materials.There are already heparin sulfate analogues that are being used for wound healing.And scientists today can,for example,make trachea out of the cells seeded from the patient.One of the first stem cell drugs has been approved for graft-versus-host rejection,and there are more stem cell therapies entering clinical development right now.This is a dramatically changing research and also how regulators have to think.This is a whole new space.We have to start developing cells now and growing cells consistently in order to make the regulators comfortable with that consistency and also to think about how we are going to make these therapies commercially viable and available around the world.There are a lot of very complex issues to deal with,but our understanding of how to use stem cells is growing year by year.And we'll start to see stem cells being used in regenerative medicine in the cardiovascular space for heart disease,and to regenerate pancreas and other organs.This is a space to watch but there will be a lot of complexity from regulatory perspective going forwards.(https://www.daowen.com)
G6n6 and Olig-bas6d Th6rapy
Let's look at genomics and gene-based therapies.Gene therapy has long been seen as a promising way to treat numerous diseases.But it was only in 2012 that EU granted the first regulatory approval of a drug for a very small orphan disease.It will likely be a long time before regulators get comfortable with the risk-benefit ratio for gene-based therapies.However,as the regulators get more comfortable with this approach,it will be easier for the researchers to move these therapies forward.There are now multiple Oligonucleotideplatform-based therapies.With compounds in development that are showing evidence and proof of mechanism,these Oligonucleotide DNA-based therapies are now entering clinical development and getting to patients.The challenge in the future will be to develop delivery vectors that allow efficient entry into a cell and for them to be targeted to the right tissue.
Drug D6liv6ry Syst6ms
Imagine if it is possible to have an implantable pump,the size of a matchstick,to deliver medication for the diabetes patients for a year.Those are the kinds of pumps and devices that we are starting to see now and they can really transform the quality of life of the patients.We are also now starting to see nanomedicines that detect changes and problems at molecular and cellular levels and begin to treat them before the expression of the traditional symptoms.There are early examples from a number of device companies around the world,and ultimately these highly targeted therapies will help with risk-benefit profiles and the ability to treat difficult diseases.
Finally,Global Mark6tplac6
The geography of biopharmaceutical business is going to continue to change.Look at what's happening in China and Brazil.The middle classes are growing,and healthcare spending in these regions is going to increase to over$500 billion and$363 billion respectively in these two countries alone.As developing countries develop further,we will start to see a shift away from just thinking about the developing world and much more business being done with innovative medicines becoming more accessible to patients in these areas.And of course,with the aging population,there is a rise of chronic diseases such as Alzheimer's and cardiovascular disease.And so the unmet need is to going to remain high around the globe in terms of innovative medicines being delivered to patients.
The next couple of decades will be very exciting,and we expect to see great advances in healthcare.